$ICU

SeaStar Medical Holding Corporation filed an amended S-1 registration to allow for the resale of up to 65,068 shares of common stock by existing securityholders, including shares tied to Private Placement and PIPE warrants. While the company itself will not receive proceeds from the resales, it stands to gain approximately $74.0 million if all outstanding warrants are fully exercised for cash. The filing also provides updates on recent corporate actions, such as reverse stock splits and the dismissal of a class-action lawsuit, and details the company's SCD therapy for acute kidney injury and other critical conditions, highlighting FDA approvals and ongoing clinical trials.